From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated)

Author： Short Mary A.   Schlichting Douglas   Qualy Rebecca L.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.22, Iss.12, 2006-12, pp. : 2525-2540

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

When a single pivotal trial should not be enough–the case of drotrecogin-alfa (activated)

By Wiedermann Christian  

Intensive Care Medicine, Vol. 32, Iss. 4, 2006-04 ,pp. : 604-604

Springer Publishing Company

Access to resources Recommend Favorite

International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy

By Dhainaut Jean-François    

Current Medical Research and Opinion, Vol. 24, Iss. 4, 2008-04 ,pp. : 1187-1197

Informa Healthcare

Access to resources Recommend Favorite

From Bench to Bedside in Neuropsychology

By  

Cambridge Quarterly of Healthcare Ethics, Vol. 26, Iss. 4, 2017-09 ,pp. : 705-709

Cambridge University Press

Access to resources Recommend Favorite

Safety of drotrecogin alfa (activated): a fair comparison requires consistent definitions

By Williams Mark   Macias William   Rustige Joerg  

Intensive Care Medicine, Vol. 33, Iss. 8, 2007-08 ,pp. : 1487-1488

Springer Publishing Company

Access to resources Recommend Favorite

A Multicenter Evaluation of the Safety of Drotrecogin Alfa (Activated) in Patients with Baseline Bleeding Precautions

By  

Current Drug Safety, Vol. 7, Iss. 1, 2012-02 ,pp. : 3-7

Bentham Science Publishers

Access to resources Recommend Favorite